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Background
Dendritic cell-targeting antibodies (e.g. anti-DEC-205)
are used to deliver HIV vaccine immunogens for antigen
presentation. As antibodies contain sequences that con-
tribute to immunosuppression induced via regulatory T
cells, we are modifying the anti-DEC-205 sequence to
reduce its tolerogenicity to make it an effective HIV vac-
cine delivery vehicle.
Methods
IgG sequences were computationally screened for T-cell
epitopes using EpiMatrix. Class II HLA competition bind-
ing assays were performed to validate predicted epitope
peptides. T cell functional and immunophenotyping
assays were performed using peptide-stimulated PBMCs
provided by healthy human donors.
Results
Six highly promiscuous HLA class II T-cell epitopes in
both the heavy and light chain constant domains of IgG
were identified computationally. Epitopes were synthe-
sized and shown to bind multiple HLA class II molecules
with high affinity. These sequences specifically upregulate
FoxP3 expression of CD4+CD25high T cells from healthy
human donors. Co-incubation of these epitopes with var-
ious self and foreign antigens leads to antigen-specific
suppression of effector T cell proliferation and cytokine
secretion and an increase in IL-10 and CTLA-4 expression
suggesting conversion of Teff to adaptive Tregs. The anti-
DEC-205 sequence was computationally screened for
putative HLA DR4-restricted, regulatory T-cell epitopes
using EpiMatrix. Epitopes were analyzed using OptiMatrix
to select mutations that will reduce epitope binding affin-
ity for HLA. Five regulatory T-cell epitopes were computa-
tionally identified. Per epitope, three modified sequences
were selected and synthesized.
Conclusion
These studies suggest that Treg epitopes in IgG may be
responsible for antigen-specific tolerance observed for
vaccine antigens targeted to dendritic cells via anti-DEC-
205. Modification of regulatory T-cell epitopes may signif-
icantly diminish tolerogenicity, enabling the use of mod-
ified anti-DEC-205 as a HIV antigen-delivery system that
obviates the dangers associated with non-specific activa-
tion of the immune system.
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